On March 17, 2026 Soley Therapeutics, a biotechnology company advancing novel therapeutics informed by integrated cell stress biology, reported STX-6398, a first-in-class drug candidate with selective anti-tumor activity through modulation of cytoskeleton-associated protein 2 (CKAP2), a previously undruggable protein central to malignant cancer progression. Preclinical data for STX-6398 will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17-22 in San Diego.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The AACR (Free AACR Whitepaper) presentation will describe the discovery and preclinical characterization of STX-6398, an oral small molecule that modulates CKAP2 and its downstream signaling pathways. Studies demonstrate selective anti-tumor activity in vitro and in vivo, with efficacy observed across preclinical models following oral administration. These data support advancing STX-6398 as a new therapeutic opportunity for CKAP2-expressing cancers.
"CKAP2 sits at the intersection of microtubule dynamics and malignant progression, shaping proliferation, migration, and angiogenesis," said Yerem Yeghiazarians, M.D., Co-Founder and Chief Executive Officer of Soley Therapeutics. "The data to be presented at AACR (Free AACR Whitepaper) demonstrate that it is possible to pharmacologically modulate CKAP2 with an oral small molecule and achieve meaningful anti-tumor activity across multiple preclinical models. STX-6398 is one of many first-in-class candidates from Soley’s integrated cell stress platform and validates that our approach can enable drugging targets long considered inaccessible."
Soley’s AACR (Free AACR Whitepaper) 2026 Presentation Details
Title: CKAP2 Modulation with a Novel Small Molecule Results in Excellent In-Vitro and In-Vivo Anti-Tumor Activity
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Targets and Pathways
Day and Time: April 20, 2:00 PM to 5:00 PM PDT
Location: Poster Section 15
Poster Number: 3043
(Press release, Soley Therapeutics, MAR 17, 2026, View Source [SID1234663575])